What is Mometasone Market?
Mometasone is a corticosteroid that is used to treat a variety of skin conditions as well as asthma. Mometasone diffuses through the cell membrane and stimulates pathways that reduce inflammation in the case of inflammatory skin disorders. Dermatitis, psoriasis, and allergic rhinitis are examples of inflammatory skin disorders. Mometasone market growth is fueled by an increase in the prevalence of inflammatory skin disorders. During the forecast period, the rise in the geriatric population is expected to drive mometasone market growth. Increasing personal aesthetics concerns will boost the mometasone market in the coming decade.
The market study is being classified and major geographies with country level break-up.
Glenmark Pharmaceuticals (India), Hikma Pharmaceuticals (United Kingdom), Aurisco Pharma (China), Perrigo Company plc (Ireland), Bayer AG (Germany), Hubei Hengan Fulin Pharmaceutical Co., Ltd. (China), Unilab Chemicals & Pharmaceuticals Pvt. Ltd. (India), Shanghai Pharmaceuticals Holding Co., Ltd. (China), Zhejiang Xianju Pharmaceutical Co., Ltd. (China) and Symbiotec Pharma (India) are some of the key players profiled in the study.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Mometasone market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Mometasone market by Type, Application and Region.
On the basis of geography, the market of Mometasone has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Inflammatory Skin Disorders
- Rise in Geriatric Population
- Growing Patient Population Suffering from Asthma
- Rising Investment by Key Players
- Side Effects associated with Mometasone
- Increasing Personal Aesthetics Concern
- Rising Collaborative Research and Development Activities among Leading Biopharmaceutical Players
- Pricing Competition among Market Players
February 2020, Hikma Pharmaceuticals and Glenmark Pharmaceuticals announced a collaboration to commercialize Olopatadine hydrochloride and mometasone furoate nasal spray used in the treatment of seasonal allergic rhinitis.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry
Frequently Asked Questions (FAQ):
1. Which factors would majorly drive the Mometasone Market?
"Increased Prevalence of Inflammatory Skin Disorders
" is seen as one of major growth factors of Mometasone Market in years to come.
2. Can we have customized study for Mometasone Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.